Literature DB >> 16775249

Panniculitis during dasatinib therapy for imatinib-resistant chronic myelogenous leukemia.

Sarit Assouline, Pierre Laneuville, Carlo Gambacorti-Passerini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16775249     DOI： 10.1056/NEJMc053425

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

Review 1.  Chronic myeloid leukemia: reminiscences and dreams.

Authors:  Tariq I Mughal; Jerald P Radich; Michael W Deininger; Jane F Apperley; Timothy P Hughes; Christine J Harrison; Carlo Gambacorti-Passerini; Giuseppe Saglio; Jorge Cortes; George Q Daley
Journal:  Haematologica       Date:  2016-05       Impact factor: 9.941

2.  Mimicker of necrotising fasciitis with systemic inflammatory response syndrome: recurrent necrotising Sweet's syndrome associated with chronic myelogenous leukaemia.

Authors:  Kensuke Nakanishi; Mitsuyo Kinjo
Journal:  BMJ Case Rep       Date:  2016-03-31

3.  Xanthelasma palpebrarum: a new side effect of nilotinib.

Authors:  Irmak Sayin; Meltem Ayli; Ali Kemal Oğuz; Güldane Cengiz Seval
Journal:  BMJ Case Rep       Date:  2016-01-12

4.  Moving on up: Second-Line Agents as Initial Treatment for Newly-Diagnosed Patients with Chronic Phase CML.

Authors:  Marie P Shieh; Masato Mitsuhashi; Michael Lilly
Journal:  Clin Med Insights Oncol       Date:  2011-06-23

5.  Recurrent Subcutaneous Sweet's Disease in a Myelofibrosis Patient Treated with Ruxolitinib before Allogeneic Stem Cell Transplantation.

Authors:  Teppei Sakoda; Yoko Kanamitsu; Yasuo Mori; Kensuke Sasaki; Etsuko Yonemitsu; Konosuke Nagae; Goichi Yoshimoto; Kenjiro Kamezaki; Koji Kato; Katsuto Takenaka; Toshihiro Miyamoto; Masutaka Furue; Hiromi Iwasaki; Koichi Akashi
Journal:  Intern Med       Date:  2017-08-21       Impact factor: 1.271

6.  Severe toxicity of skin rash, fever and diarrhea associated with imatinib: case report and review of skin toxicities associated with tyrosine kinase inhibitors.

Authors:  Xuan Huang; Samir Patel; Nasir Ahmed; Karen Seiter; Delong Liu
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.